There is an ongoing shift toward many cancer types being treated as maintenance diseases, which places a significant financial burden not only on patients, but also payers and providers within the health care industry.
Chris Guinther, PharmD, RPh
Advertisement
Articles by Chris Guinther, PharmD, RPh
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Scrutiny of GLP-1 Compounding Is Just Getting Started, Expert Says
2
Menin Inhibitors in AML: Frequently Asked Questions
3
From Misnomer to Meaning: A Patient-Centered Shift from PCOS to PMOS
4
FDA Approves Veligrotug-vvze as First Agent With Data in Both Active and Chronic Thyroid Eye Disease
5